Search results
Showing 1551 to 1600 of 3041 results for all
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]
In development Reference number: GID-TA11373 Expected publication date: TBC
NICE has developed a medtech innovation briefing (MIB) on OSNA for colon cancer staging
Find out which guidance and quality standards are awaiting development
MRI fusion biopsy systems for diagnosing prostate cancer (HTG678)
Evidence-based recommendations on MRI fusion biopsy systems for diagnosing prostate cancer.
Early value assessment (EVA) guidance on digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD.
This indicator covers the proportion of women aged 53 to 70 years whose record shows a breast screening test has been performed within the last 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG84
Early value assessment (EVA) guidance on guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of anxiety or low mood.
Evidence-based recommendations on leniolisib (Joenja) for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over.
Burosumab for treating X-linked hypophosphataemia in adults (TA993)
Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.
In development Reference number: GID-TA11733 Expected publication date: 26 August 2026
Service user experience in adult mental health services (QS14)
This quality standard covers improving the experience of people using adult NHS mental health services. It describes high-quality care in priority areas for improvement.
View quality statements for QS14Show all sections
Sections for QS14
- Quality statements
- Quality statement 1: Empathy, dignity and respect
- Quality statement 2: Decision making
- Quality statement 3: Involvement to improve services
- Quality statement 4: Contacts for ongoing care
- Quality statement 5: Access to services
- Quality statement 6: Joint care planning
- Quality statement 7: Inpatient contact with staff
Preventing suicide in community and custodial settings (NG105)
This guideline covers ways to reduce suicide and help people bereaved or affected by suicides. It aims to:
NICE has developed a medtech innovation briefing (MIB) on Helge for detecting haemolysis .
NICE has developed a medtech innovation briefing (MIB) on RenalSense Clarity RMS for acute kidney injury .
NICE has developed a medtech innovation briefing (MIB) on SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea .
Galaxy UNYCO for temporary stabilisation of lower limb fractures (MIB166)
NICE has developed a medtech innovation briefing (MIB) on Galaxy UNYCO for temporary stabilisation of lower limb fractures .
Evidence-based recommendations on 3C Patch for treating diabetic foot ulcers.
In development Reference number: GID-TA11340 Expected publication date: TBC
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]
Awaiting development Reference number: GID-TA11215 Expected publication date: 07 May 2026
Osteoporosis: bone sparing agents (75 years and over) (IND92)
This indicator covers the percentage of patients aged 75 or over with a fragility fracture on or after 1 April 2012, who are currently treated with an appropriate bone-sparing agent. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM31
This indicator covers the percentage of patients aged 50 or over and who have not attained the age of 75, with a record of a fragility fracture on or after 1 April 2012, in whom osteoporosis is confirmed on DXA scan, who are currently treated with an appropriate bone-sparing agent. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM30
Guidance on the use of ultrasound locating devices for placing central venous catheters (TA49)
Evidence-based recommendations on using ultrasound locating devices for placing central venous catheters into the internal jugular vein.
Evidence-based recommendations on the Foker technique for long-gap oesophageal atresia. This involves pulling slightly on the broken ends of the oesophagus to encourage them to grow towards each other so they can be stitched together to form a complete oesophagus.
View recommendations for IPG153Show all sections
Sections for IPG153
Evidence-based recommendations on sotorasib (Lumykras) for previously treated KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults.
Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)
Evidence-based recommendations on vedolizumab (Entyvio) for treating moderate to severe ulcerative colitis in adults.
Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic, hormone-relapsed prostate cancer for people in whom chemotherapy is not yet clinically indicated.
Ocrelizumab for treating primary progressive multiple sclerosis (TA585)
Evidence-based recommendations on ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis in adults.
Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)
Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for multiple myeloma after 1 treatment with bortezomib in adults.
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)
Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.
Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.
Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (AMR2)
Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (HTG320)
Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative colitis) and non-inflammatory bowel diseases (such as irritable bowel syndrome).
Drug-eluting stents for treating coronary artery disease: late-stage assessment (HTG747)
Late-stage assessment (LSA) guidance on drug-eluting stents for treating coronary artery disease.
View recommendations for HTG747Show all sections
Danis stent for acute oesophageal variceal bleeding (HTG574)
Evidence-based recommendations on Danis stent for acute oesophageal variceal bleeding.
NICE has developed a medtech innovation briefing (MIB) on Biopatch for venous or arterial catheter sites .
NICE has developed a medtech innovation briefing (MIB) on Permacol for treating anal fistulae .
NICE has developed a medtech innovation briefing (MIB) on ADXBLADDER for detecting bladder cancer .
Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care (HTG607)
Evidence-based recommendations on Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care.
This quality standard covers the assessment and management of non-specific low back pain and sciatica in young people and adults aged 16 years and over. It describes high-quality care in priority areas for improvement.
View quality statements for QS155Show all sections
Sections for QS155
- Quality statements
- Quality statement 1: Risk stratification
- Quality statement 2: Referrals for imaging
- Quality statement 3: Self-management
- Quality statement 4: Gabapentinoids, antiepileptics, antidepressants and paracetamol for low back pain without sciatica
- Quality statement 5: Opioids for chronic low back pain without sciatica
- Quality statement 6: Spinal injections
- Update information
Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)
Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant.
Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments (TA1091)
Evidence-based recommendations on tarlatamab (IMDYLLTRA) for treating extensive-stage small-cell lung cancer after 2 or more treatments in adults.
Show all sections
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)
Evidence-based recommendations on bevacizumab (Avastin) and cetuximab (Erbitux) for treating metastatic colorectal cancer in adults.
Mechanical thrombectomy devices for acute ischaemic stroke (MIB153)
NICE has developed a medtech innovation briefing (MIB) on mechanical thrombectomy devices for acute ischaemic stroke .
High dose rate brachytherapy for carcinoma of the cervix (IPG160)
Evidence-based recommendations on high dose rate brachytherapy for carinoma of the cervix. This involves giving radiation at a high dose rate to the cervix (reducing the timeframe compared with low or medium dose rates) to treat the cancer.
View recommendations for IPG160Show all sections
Sections for IPG160
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]
In development Reference number: GID-TA11096 Expected publication date: TBC
In development Reference number: GID-TA10726 Expected publication date: 25 February 2026
Evidence-based recommendations on isatuximab (Sarclisa) plus bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma in adults when an autologous stem cell transplant is unsuitable.
Show all sections
Evidence-based recommendations on garadacimab (Andembry) for preventing recurrent attacks of hereditary angioedema in people 12 years and over.
Evidence-based recommendations on abemaciclib (Verzenios) with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence in adults.
Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making